Navigation Links
SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA
Date:2/14/2008

IRVINE, Calif., Feb. 14 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats on public equities that are in the news and driving markets today.

Investors can view all of SectorWatch.biz MarketStats free of charge by visiting: http://www.SectorWatch.biz -- Click on MarketStats

Today's MarketStats on Healthcare and Biotechnology companies include: CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), Boston Scientific Corp. (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Cardium Therapeutics Inc. (Amex: CXM) and Genentech Inc. (NYSE: DNA).

To view a complete profile on CardioVascular Bio Therapeutics, Inc., visit our financial courier StockUpTicks.com (http://www.stockupticks.com).

Our MarketStats provide snapshots and analysis on public equities making news, driving industry sectors and affecting the markets. SectorWatch.biz is powered by Market Pathways, a leader in the representation of Small Cap equities for over twenty-five years. We are your discovery zone for under-followed stocks shaping the market.

Interested investors may subscribe for FREE to our StockUpTicks newsletter featuring a treasure trove of promising companies, daily market movers and free personal investment information -- visit http://stockupticks.com/register.html. D.R. Clark of Market Pathways is a member of the National Association of Securities Dealers, CRD # 4518163.

Contact us directly to have your company featured in StockUpTicks.com or SectorWatch.biz. For D.R. Clark's perspective on personal finance and the markets visit http://www.ClarkReport.com

Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations, Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.

This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has been granted twenty thousand restricted shares of CVBT common stock by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.


'/>"/>
SOURCE SectorWatch.biz
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
2. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
3. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
4. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
5. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
9. HHS Issues First Department-Wide Report on Personalized Health Care
10. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):